-transparent.png){kind=logo}
Options for treating disseminated Mycobacterium avium complex (MAC) disease have improved. However, efficacy is not always certain, resistance is common and rapidly bactericidal agents would improve efficacy and prevent resistance. Certain oxazolidinones were tested against MAC strains and inhibited growth at expected serum concentrations or lower. Activity correlated with hydrophobicity and one agent was bactericidal at concentrations two to five times greater than the MIC.
Related Publications
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
February 1993,
Archives of internal medicine,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
October 2021,
Journal of medical microbiology,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
July 1989,
The Journal of antimicrobial chemotherapy,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
February 1990,
Antimicrobial agents and chemotherapy,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
April 2006,
Journal of chemotherapy (Florence, Italy),
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
May 1987,
Diagnostic microbiology and infectious disease,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
September 1989,
The Journal of antimicrobial chemotherapy,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
December 1998,
Antimicrobial agents and chemotherapy,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
February 2017,
Antimicrobial agents and chemotherapy,
J Peters, and
K L Kondo, and
R K Lee, and
C K Lin, and
C B Inderlied
October 1996,
Antimicrobial agents and chemotherapy,
